The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

A new study published in the Journal of the National Cancer Institue found that patients taking TZD (thiazolidinedione drugs, including Actos and Avandia) for more than five years had two to three times the incidence of bladder cancer as patients taking sulfonyurea (diabetes medication).

The study was performed by University of Pennsylvania researchers and is yet another link in the chain between bladder cancer and Actos.

Ronac Mamtani, MD, the head University of Pennsylvania researcher said that the stated that, “doctors who care for patients with diabetes should be very aware of any bladder-related symptoms patients might be having, like blood in the urine, and take steps to further evaluate those issues.”

If you have, or someone you know has, developed bladder cancer after taking Actos and you wish to discuss your legal rights, please contact the attorneys of Sheller, P.C. at 888-883-2299, or write us at

One Comment

  1. Gravatar for Daniel Haszard

    Actos is produced by Takeda Industries and co-marketed by Eli Lilly.

    Eli Lilly Zyprexa can *cause* diabetes.

    I took Zyprexa olanzapine a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.

    Eli Lilly's #1 cash cow Zyprexa drug sale $67 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company Eli Lilly also is a big profiteer of diabetes treatment.

    (Actos works as an insulin *sensitizer*)

    Sooooo,Eli Lilly pushes a drug (Zyprexa) that can cause diabetes.... then turn around sell you the drugs (Actos) to treat the diabetes that in turn can cause cancer!

    What a terrible conflict of interest!

    -- Daniel Haszard

Comments are closed.

Of Interest